Cite
HARVARD Citation
Blauvelt, A. et al. (2019). Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. Journal of the European Academy of Dermatology and Venereology. pp. 546-552. [Online].